GSK/Par Paxil Generic Deal Upheld In Court; FTC Closes Patent Investigation
Executive Summary
GlaxoSmithKline's "authorized" generic Paxil agreement with Par does not raise any antitrust concerns, Chicago federal court Judge Richard Posner ruled Oct. 29
You may also be interested in...
Mylan Challenge To “Authorized” Generics May Shift To Antitrust Arguments
Mylan could turn to antitrust laws as an avenue for renewing a court challenge against "authorized" generics after dropping its lawsuit against FDA
Mylan Challenge To “Authorized” Generics May Shift To Antitrust Arguments
Mylan could turn to antitrust laws as an avenue for renewing a court challenge against "authorized" generics after dropping its lawsuit against FDA
Bristol/Teva “Authorized” Generic Agreement Approved By FTC
The Federal Trade Commission is giving its formal blessing to an "authorized" generic agreement between Bristol-Myers Squibb and Teva involving the first generic version of Paraplatin (carboplatin)